Cytokinetics, Inc. (NASDAQ:CYTK) announced the recent publication of three peer-reviewed manuscripts relating to tirasemtiv and fast skeletal muscle troponin activation in the journals PLOS ONE, Muscle & Nerve, and the American Journal of Respiratory and Critical Care Medicine. Cytokinetics, Inc. (NASDAQ:CYTK) stock opened today at $4.42 and is currently trading at $4.47. The stock showed a negative weekly performance of -0.45%.
Ariad Pharmaceuticals, Inc (NASDAQ:ARIA), the controversial small-cap bio pharma company has now taken some steps in the right direction towards rebuilding the company’s Iclusig brand with release of its Q1 earnings results. For the reported quarter, the total revenue rose 82% to $11.8M & it included $8 million of sales of the company’s leukemia drug-Iclusig that had been temporarily pulled out from the market towards the end of 2013 for a few weeks & had been relabeled with some more inclusive safety-warnings. This is a 25% rise from the previous year. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $6.36, in current trading session and currently is at $6.38, by gaining 0.31%. The 52 week range of $2.15 – $23.00. Company’s market capitalization is 1.19 billion.
Gilead Sciences (NASDAQ:GILD) reported that it has achieved its primary and secondary endpoints in a placebo-controlled, phase 2a challenge study of GS-5806 in healthy adult patients intranasally infected with respiratory syncytial virus. Gilead Sciences, Inc. (NASDAQ:GILD) stock is currently trading at $81.68. The EPS of the stock is 2.71. Company’s market capitalization is 125.43 billion.
Biogen Idec (NASDAQ:BIIB)’s EVP Steven Holtzman sold 1,221 shares of Biogen Idec stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $289.15, for a total transaction of $353,052.15. Following the completion of the sale, the executive vice president now directly owns 5,749 shares of the company’s stock, valued at approximately $1,662,323. Biogen Idec Inc. (NASDAQ:BIIB) stock opened the session at $290.12, and now is at $292.23. The 52 week range of the Biogen Idec Inc. (NASDAQ:BIIB) stock remained $194.66 – $358.89 and the day range was $290.12 – $294.68.
The drug maker Questcor Pharmaceuticals Inc (NASDAQ:QCOR) just got over a major hurdle in its efforts to merge into a fellow drug company. The U.S. Federal Trade Commission announced the termination of the antitrust review of the deal between Questcor and Mallinckrodt PLC (NYSE:MNK). Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) stock opened today at $92.04 and is currently trading at $93.00. The stock showed a positive weekly performance of 6.57%.